An independent information document for nurses

Is there a difference between recommending flu, RSV and COVID-19 vaccinations in children? What is meant by preventing secondary diseases and other societal wider benefits? ...

Flu is the forgotten killer. What new vistas of vaccinology opened up after the COVID-19 pandemic? In what ways can flu treatments change as a consequence of lessons learned?

How has the world of travel medicine evolved? What multiple roles do vaccinations have? What impact did the COVID-19 pandemic have on travel behaviour? Why is it so important to keep up to date on the current epidemiological situation?

This interactive dashboard provides a weekly integrated epidemiological summary for influenza, RSV and severe acute respiratory syndrome coronavirus 2 for the EU/EEA and the WHO European Region

Genetic changes to avian influenza viruses have led to spread among many wild species, creating an uncontrollable global outbreak.

Highly pathogenic avian influenza (HPAI) H5N1 activity has intensified globally since 2021, increasingly causing mass mortality in wild birds and poultry and incidental infections in mammals.

European health ministers agreed on a target of vaccinating 75% of older people in 2009 ‒ almost all countries are still falling short.

On February 2023, the French National Authority for Health (HAS) recommended extending flu shots to children aged 2-17 years without comorbidities.

Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and impairs hippocampal responses and memory. These findings provide a possible explanation for neurocognitive symptoms associated with viral persistence in Long COVID.

Since SARS-CoV-2 BA.5 (Omicron) emerged and spread in 2022, Omicron lineages have markedly diversified.

In the last three years, extensive research has demonstrated the safety and efficacy of COVID-19 vaccines. These vaccines have played a critical role in reducing mortality and hospitalization rates.